{
  "docId": "019de074-2691-7523-92d7-a01a3837be3d",
  "docSlug": "fa8fb15584528290578ab0c38f82e3e3",
  "documentTitle": "argenx SE | Investor Conference Presentation Deck | 22 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 22,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "propose_solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide highlights the mechanism of action (pH/Ca2+ switch, no effector function, optimal recycling) and the clinical pipeline status for MMN, delayed graft function, and dermatomyositis.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2691-7523-92d7-a01a3837be3d/15",
  "deckHref": "/decks/019de074-2691-7523-92d7-a01a3837be3d",
  "deckJsonHref": "/decks/019de074-2691-7523-92d7-a01a3837be3d.json",
  "deckAnchorHref": "/decks/019de074-2691-7523-92d7-a01a3837be3d#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.15,
        "x": 0.83,
        "y": 0.01
      },
      "kind": "callout",
      "text": "clinical Broaden immunology pipeline",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "122cf188-b83d-4a14-86e3-fdc863268576",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.05,
        "y": 0.4
      },
      "kind": "image",
      "text": "Antibody diagram showing pH and Ca2+ switch, no effector function, and optimal recycling",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f1fda1c-edc3-4b21-a6c9-7148a2bbe904",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.55,
        "x": 0.35,
        "y": 0.35
      },
      "kind": "list",
      "text": "Indication selection starts with autoimmune diseases driven by classical and/or lectin pathway; Phase 2 proof-of-concept trial underway in multifocal motor neuropathy (MMN) with interim data expected in mid-2023; Phase 2 trials to start in delayed graft function and dermatomyositis",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca9110f9-4aa7-4c5e-b62c-5895cdf34bf0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.45,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "ARGX-117: Targets C2 at Junction of Classical and Lectin Pathways",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f1e6260-87aa-4ffb-86df-97d471d66d38",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 22,
      "from": 15,
      "beatId": "2b02df3a-6f99-4079-be65-27ef4febe9fa",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "New Bliss",
      "beatSlug": "sparkline-new-bliss",
      "evidence": "The presentation concludes with a vision for the future (new bliss).",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 15,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "a0c08e58-982f-4e3c-a9f8-0cc9206ac25a",
      "evidence": "The proposal of a solution on page 15 highlights the potential benefits of ARGX-117.",
      "position": 2,
      "objective": "Understanding the potential impact of ARGX-117",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.6,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}